<- Go Home

Anteris Technologies Global Corp.

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.

Market Cap

AUD 656.1M

Volume

20.3K

Cash and Equivalents

AUD 282.7M

EBITDA

-AUD 94.4M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

AUD 1.4M

Profit Margin

74.28%

52 Week High

AUD 7.11

52 Week Low

AUD 3.40

Dividend

N/A

Price / Book Value

2.35

Price / Earnings

-3.44

Price / Tangible Book Value

2.35

Enterprise Value

AUD 377.1M

Enterprise Value / EBITDA

-4.03

Operating Income

-AUD 96.1M

Return on Equity

59.21%

Return on Assets

-33.99

Cash and Short Term Investments

AUD 282.7M

Debt

AUD 3.7M

Equity

AUD 278.4M

Revenue

AUD 1.9M

Unlevered FCF

-AUD 52.6M

Sector

Health Care Equipment and Supplies

Category

N/A

Company Stock Pitches